Biomea Fusion Inc (NAS:BMEA)

$ 4.4772 0.2472 (5.84%) Market Cap: 160.93 Mil Enterprise Value: 19.74 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 40/100

Biomea Fusion Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Biomea Fusion Inc ADA Scientific Sessions Discussion Transcript
Jun 27, 2023
Biomea Fusion Inc to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes- Conference Call Transcript
Mar 28, 2023
Biomea Fusion Inc to Discuss FDA Clearance of IND for BMF-219 in Type 2 Diabetes Transcript
Dec 15, 2022
Biomea Fusion Inc Covalent Menin Inhibitor BMF-219's Activity in Diabetes as Presented at the 82nd American Diabetes Association Annual Conference Transcript
Jun 06, 2022

Biomea Fusion Inc Covalent Menin Inhibitor BMF-219's Activity in Diabetes as Presented at the 82nd American Diabetes Association Annual Conference Transcript

Jun 06, 2022 / 08:05PM GMT

Transcript

Operator

Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Covalent Menin Inhibitor BMF-219's Activity in Diabetes as presented at the 82nd American Diabetes Association Annual Meeting. (Operator Instructions) I would now like to hand the conference over to your host, Ramses Erdtmann. Please go ahead.

Ramses Erdtmann

Biomea Fusion - COO, President & Co-founder

Thank you, Operator. Good morning and thank you for dialing in. My name is Ramses Erdtmann. I'm the COO, President, and Co-founder of Biomea.

With me on the call today and available to answer questions are our CEO and Chairman, Tom Butler, also Co-founder of Biomea; as well as our CMO, Dr. Steve Morris; our Senior Medical Director, Dr. Sanchita Mourya; and our Associate Director of Translational Research, Priyanka Somanath.

A few words about these team members. Let me start with Steve who joined our team about two years ago first as a consultant. Steve is an internist and medical oncologist. He brings over 35 years of experience as a clinician and academic.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.